Gumflu Capsule 30mg (Oseltamivir Phosphate)

Adult dose

For the treatment of influenza A and B virus infections, administer oseltamivir 75 mg orally twice daily for 5 days. For prevention, administer 75 mg orally once daily for 10 days. It may be administered regardless of food intake. Separate dosage-adjustment instructions are available for patients with renal or hepatic impairment.

Child dose

Children aged 1 year through 12 years: Administer as a suspension or capsule according to body weight. For treatment, administer twice daily for 5 days. (Body weight ≤15kg: 30 mg twice daily, >15kg to ≤23kg: 45 mg twice daily, >23kg to ≤40kg: 60 mg twice daily, >40kg: 75 mg twice daily) Children aged 2 weeks to under 1 year: Administer 3 mg per kg of body weight orally twice daily for 5 days. For prevention, administer once daily for 10 days according to body weight. (Body weight ≤15kg: 30 mg once daily, >15kg to ≤23kg: 45 mg once daily, >23kg to ≤40kg: 60 mg once daily, >40kg: 75 mg once daily) The preventive efficacy and safety in children under 1 year of age have not been evaluated.

This medication cannot replace influenza vaccination and should be used separately from vaccinations. This medication is effective only against influenza A and B viruses, and its safety and efficacy have not been established for other infections. Rarely, neurological and psychiatric adverse reactions may occur in children and adolescents taking this medication, and caregivers should carefully observe for unusual behaviors, particularly if they manifest. Patients with a known allergy to this medication or its components should not use it. Patients with impaired renal function may need dose adjustments, and it is not recommended for patients with severe renal failure. While taking this medication, side effects such as nausea, vomiting, and headaches may occur, but most are temporary. Severe allergic reactions, liver function abnormalities, and serious skin reactions like rashes may occur, and if symptoms appear, immediate consultation with a healthcare provider is necessary. Pregnant or lactating women should consider the benefits and risks of treatment, as safety data regarding pregnant women is limited. For children, especially those under 1 year old, its safety and efficacy have not been established, and its use should be avoided. Elderly patients do not require dose adjustments, but should be carefully monitored due to declining physical functions and underlying diseases. While this medication has a low potential for interactions with other drugs, caution is warranted when used in combination with specific medications. If unusual behavior or neurological symptoms occur while taking this medication, immediate consultation with medical personnel is required. Keep this medication out of the reach of children and do not transfer it to other containers for safety.

• Convulsions
• delirium
• abnormal behavior
• nausea
• vomiting
• headache
• pain
• unstable angina
• anemia
• pseudomembranous colitis

This medication should be stored in a tightly closed container to prevent air and moisture ingress at a temperature between 1 and 30 degrees Celsius. By storing it this way, the effectiveness of the medication can be preserved for a longer period.

Appearance

A hard capsule of yellowish color containing white or light yellow powder

Package unit

10 capsules/PTP